Product Code: GMDHC7837IDB
Summary
Global Markets Direct's, 'Tetanus - Pipeline Review, H1 2016', provides an overview of the Tetanus pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Tetanus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Tetanus
- The report reviews pipeline therapeutics for Tetanus by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Tetanus therapeutics and enlists all their major and minor projects
- The report assesses Tetanus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Tetanus
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Tetanus
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tetanus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Tetanus Overview
- Therapeutics Development
- Pipeline Products for Tetanus - Overview
- Pipeline Products for Tetanus - Comparative Analysis
- Tetanus - Therapeutics under Development by Companies
- Tetanus - Therapeutics under Investigation by Universities/Institutes
- Tetanus - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Tetanus - Products under Development by Companies
- Tetanus - Products under Investigation by Universities/Institutes
- Tetanus - Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co., Ltd
- Bharat Biotech International Limited
- Biological E. Limited
- Boryung Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company, Limited
- GlaxoSmithKline Plc
- Green Cross Corporation
- Indian Immunologicals Limited
- LG Life Science LTD.
- Panacea Biotec Limited
- Prometheon Pharma, LLC
- Sanofi Pasteur SA
- Serum Institute of India Limited
- Sinovac Biotech Ltd.
- Zydus Cadila Healthcare Limited
- Tetanus - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole-cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole-cell) + tetanus) (pentavalent) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- (diphtheria + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- diphtheria + pertussis(acellular) + tetanus vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Eupenta - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GC-1107 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GC-3111A - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- LBVD - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- tetanus vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- tetanus vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- tetanus vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- VN-0103 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- VN-0105 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Tetanus - Recent Pipeline Updates
- Tetanus - Dormant Projects
- Tetanus - Discontinued Products
- Tetanus - Product Development Milestones
- Featured News & Press Releases
- Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta
- Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program
- Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine
- Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age
- Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima
- Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine
- Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets
- Jun 22, 2012: Sanofi Pasteur's Hexaxim Receives Positive Opinion From European Medicines Agency
- Mar 13, 2008: U.S. FDA Licenses DAPTACEL Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series
- Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Number of Products under Development for Tetanus, H1 2016
- Number of Products under Development for Tetanus - Comparative Analysis, H1 2016
- Number of Products under Development by Companies, H1 2016
- Number of Products under Investigation by Universities/Institutes, H1 2016
- Comparative Analysis by Late Stage Development, H1 2016
- Comparative Analysis by Clinical Stage Development, H1 2016
- Comparative Analysis by Early Stage Development, H1 2016
- Products under Development by Companies, H1 2016
- Products under Development by Companies, H1 2016 (Contd..1)
- Products under Investigation by Universities/Institutes, H1 2016
- Tetanus - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016
- Tetanus - Pipeline by Bharat Biotech International Limited, H1 2016
- Tetanus - Pipeline by Biological E. Limited, H1 2016
- Tetanus - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016
- Tetanus - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
- Tetanus - Pipeline by GlaxoSmithKline Plc, H1 2016
- Tetanus - Pipeline by Green Cross Corporation, H1 2016
- Tetanus - Pipeline by Indian Immunologicals Limited, H1 2016
- Tetanus - Pipeline by LG Life Science LTD., H1 2016
- Tetanus - Pipeline by Panacea Biotec Limited, H1 2016
- Tetanus - Pipeline by Prometheon Pharma, LLC, H1 2016
- Tetanus - Pipeline by Sanofi Pasteur SA, H1 2016
- Tetanus - Pipeline by Serum Institute of India Limited, H1 2016
- Tetanus - Pipeline by Sinovac Biotech Ltd., H1 2016
- Tetanus - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
- Assessment by Monotherapy Products, H1 2016
- Assessment by Combination Products, H1 2016
- Number of Products by Stage and Target, H1 2016
- Number of Products by Stage and Route of Administration, H1 2016
- Number of Products by Stage and Molecule Type, H1 2016
- Tetanus Therapeutics - Recent Pipeline Updates, H1 2016
- Tetanus - Dormant Projects, H1 2016
- Tetanus - Dormant Projects (Contd..1), H1 2016
- Tetanus - Discontinued Products, H1 2016
List of Figures
- Number of Products under Development for Tetanus, H1 2016
- Number of Products under Development for Tetanus - Comparative Analysis, H1 2016
- Number of Products under Development by Companies, H1 2016
- Number of Products under Investigation by Universities/Institutes, H1 2016
- Comparative Analysis by Late Stage Development, H1 2016
- Comparative Analysis by Clinical Stage Development, H1 2016
- Comparative Analysis by Early Stage Products, H1 2016
- Assessment by Monotherapy Products, H1 2016
- Assessment by Combination Products, H1 2016
- Number of Products by Targets, H1 2016
- Number of Products by Stage and Targets, H1 2016
- Number of Products by Routes of Administration, H1 2016
- Number of Products by Stage and Routes of Administration, H1 2016
- Number of Products by Molecule Types, H1 2016
- Number of Products by Stage and Molecule Types, H1 2016
